Acquisition of the rare neurological disease treatment business through the acquisition of IntraBio

An individual M&A transaction to acquire all shares of IntraBio and the global rights to treatments for rare neurodegenerative and hereditary neurological diseases, including AQNEURSA. A theme focused on entering and expanding in the rare neurological disease business, including approved drugs.